Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Want to cut your energy bills? Here’s how five experts are doing it 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
PARIS and NEW YORK, March 24, 2016 -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company focused on the development of new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it has completed a private placement with U.S. institutional investors totalling €5.54 million. Directly following the U.S. capital increase, the Company raised an additional €3.04 million through a public offering in Europe through existing shareholders, for a total of €8.6 million.
In these two placements, the Company issued 1,429,973 shares at €6.00 per share, and warrants to purchase an additional 714,986 shares at an exercise price of €7.75 per share for 30 months. The warrants, if fully exercised, would generate additional proceeds of €5.5 million. Participation in the European rights offering was open to shareholders of Quantum Genomics as of March 16, 2016.
“This capital increase is consistent with our expansion strategy, which includes the recently announced establishment of a U.S. Clinical Advisory Board and the opening of an office in New York on March 1st, 2016. The funds raised will enable us to further advance, in the U.S. and various European countries, the Phase II clinical trials of our products for the treatment of resistant hypertension and heart failure,” said Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics.
Maxim Group LLC acted as the exclusive placement agent in the United States, and Invest Securities managed the subscriptions in France.
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC). The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
CONTACTS Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77 Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 [email protected] ACTUS finance et communication (Europe) Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 [email protected] The Ruth Group (U.S.) Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592
